Latest Safety News

Arika Resources has expanded its exploration footprint at the Yundamindra Gold Project with over 25 new high-priority gold targets identified and a $3.2 million capital raise to fast-track drilling programs. The company awaits assay results from recent drilling that could redefine the project's scale.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its clinical trial for Autosomal Dominant Optic Atrophy, marking a pivotal step in developing a treatment for this currently untreatable blinding disease.

Constellation Technologies reports a slight decline in quarterly sales but marks a strategic breakthrough by deploying its Callisto Food Safety & Compliance system into the Aged Care sector, positioning itself for growth in a highly regulated market.

CuFe Limited has announced a substantial update to its Orlando Copper-Gold Mineral Resource Estimate, nearly doubling copper and gold quantities and significantly enhancing the Tennant Creek Project's overall resource base.

Berkeley Energia reports promising lithium and rubidium mineralisation at its Conchas Project while advancing a $1 billion arbitration claim against Spain over regulatory setbacks at Salamanca.

INOVIQ's December quarterly update reveals significant progress in its cancer diagnostic and therapeutic programs, including a highly accurate ovarian cancer screening test and promising breast cancer therapeutics, supported by growing EXO-NET customer adoption and a solid cash position.

Winsome Resources has filed a key Technical Report for its Adina Lithium Project and extended payment terms for the Renard Operation acquisition, marking significant progress in project development and regulatory engagement.

Amplia Therapeutics has completed enrolment for its ACCENT Phase 2a trial in advanced pancreatic cancer two months early, reporting encouraging partial response rates and improved patient outcomes.

Native Mineral Resources has secured key Queensland gold assets and is advancing refurbishment of the Blackjack Processing Plant, targeting production restart by Q3 2025. The company’s recent capital raises underpin its ambitious development plans.

Imugene Limited reports durable patient responses in multiple cancer immunotherapy trials and strengthens its financial position with a $46 million convertible note deal and a substantial R&D tax refund.

GreenHy2 Limited reports a slight cash decline but strengthens its foothold in renewable energy with key partnerships and strategic pivots in hydrogen storage technology.

Immutep Limited has initiated its pivotal Phase III trial for eftilagimod alfa in first-line non-small cell lung cancer, supported by compelling survival outcomes from ongoing studies and a robust cash position expected to fund operations through 2026.